CMS proposes the 2026 Physician Fee Schedule (PFS), addressing payment disparities in oncology, but the community oncology community warns of financial threats from the Inflation Reduction Act. Updates reflect late Tuesday release of the proposed 2026 schedule for the Hospital Outpatient Prospective Payment System.
The CMS Bundled Payment for Care Improvement (BPCI) Advanced model was successful at reducing spending for outpatient procedures for patients receiving back and neck except spinal fusion treatments or procedures.
Robert Kratzke, MD, urged insurance providers to prioritize fast biomarker testing in non–small cell lung cancer, saying it’s both cost-effective and life-saving.
Survival models using electronic health record data show promise in predicting progression to proliferative diabetic retinopathy in patients with type 2 diabetes.
Jayme Ambrose, DNP, RN, CCM, of Adobe Population Health, explores how addressing social determinants of health transforms maternal care delivery, reduces disparities, and improves outcomes for mothers and infants.
A new trial finds guselkumab is highly effective and well tolerated for moderate to severe scalp psoriasis in individuals with diverse skin tones.
With few real-life studies that have specifically focused on how atopic dermatitis (AD) affects patients living with the chronic inflammatory skin condition in Latin American countries, the present authors investigated dupilumab-related outcomes among 100 patients using SCORing Atopic Dermatitis (SCORAD) index values.
Medicare inflation rebates fail to curb rising drug prices, highlighting the need for further policy action to control costs.
Europe seizes leadership in global health as US funding cuts create disparities, HHS is sued by multiple medical groups, and new findings highlight gaps in care.
New insights highlight clinician support for shared survivorship care and identify key factors for effective implementation.
Women who developed a cardiovascular disease or type 2 diabetes were at a higher risk of developing breast cancer post menopause, a recent study found.
The hemoglobin, albumin, lymphocyte, and platelet (HALP) score can help to guide treatment decisions in patients living with non–small cell lung cancer (NSCLC).
Obecabtagene autoleucel showed over 70% response rates in relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL), demonstrating efficacy across all age groups in recent trials.
Researchers found a 30% increased risk of cardiovascular events in patients whose diagnosis was delayed by more than a year after an elevated blood pressure reading.
Many FDA accelerated approvals continue to rely heavily on surrogate endpoints, raising ongoing uncertainty about the true clinical benefits of these therapies.
Prenatal exposure to air pollution was associated with childhood obesity risk in a recent study, highlighting the urgent need for environmental health awareness.
Sotatercept-csrk was first approved in 2024 to treat pulmonary arterial hypertension (PAH) in adults based on results seen in the phase 3 STELLAR trial.
Long-term results from the phase 2 OVARIO trial (NCT03326193) highlight the effectiveness of niraparib plus bevacizumab as maintenance therapy in patients with advanced ovarian cancer.
During the Reshaping Rx: Navigating 2025 Drug Pricing Policies webinar, panelists discussed the Most Favored Nation executive order, bills aimed at pharmacy benefit managers (PBMs), and other drug pricing policies.
The Trump administration's policies reshape global health dynamics, presenting Europe with both challenges and opportunities for leadership in health governance.
Long-term exposure to water contaminants, even below the regulatory limits, significantly increases the risk of chronic kidney disease.
Air pollution exposure, both before and after birth, significantly escalates the risk of respiratory infections in children.
New research reveals critical gaps in treatment for advanced non–small cell lung cancer (NSCLC), emphasizing the need for innovative therapies to improve patient outcomes.
Glucagon-like peptide-1 (GLP-1) receptor agonists significantly enhance overall survival in patients with ovarian cancer, offering a promising adjunct to traditional treatments.
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
There are molecular testing gaps in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) treatment, highlighting the need for improved testing and targeted therapy integration.
Significant demographic differences were found when evaluating the use of depression services in people living with HIV and depression.
Findings underscore the potential limitations of using systemic inflammatory indices like the Dietary Inflammatory Index and Systemic Immune-Inflammation Index to assess organ-specific conditions.
The recent decision in Kennedy v Braidwood could give Robert F. Kennedy Jr, secretary of HHS, the ability to remove all members of the US Preventive Services Task Force (USPSTF) if desired, according to Jeffrey Fitzgerald, JD.
Significant gaps in arthritis subtype awareness among US adults underscore the need for improved health literacy and more targeted public health efforts.
259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512
© 2025 MJH Life Sciences®
All rights reserved.
